Researchers have identified two existing cancer medications—letrozole and irinotecan—that show potential in reversing brain changes associated with Alzheimer’s disease. By targeting different types of brain cells, this combination therapy reduced harmful tau protein clumps and improved memory in mouse models, according to findings published in the journal Cell.
How can existing cancer drugs treat Alzheimer’s?
The research team at UC San Francisco utilized computational tools to analyze how Alzheimer’s alters gene expression in the brain. According to computational biologist Marina Sirota, these tools allowed the team to “tackle the complexity directly” by searching the Connectivity Map database for drugs capable of reversing those specific gene expression changes. The researchers cross-referenced these findings with clinical records of patients who had received these treatments for cancer, noting a decreased risk of developing Alzheimer’s in those individuals. Letrozole, typically used for breast cancer, and irinotecan, used for colon and lung cancer, emerged as the most promising candidates.
Why is a combination therapy approach necessary?
Traditional drug development often focuses on a single gene or protein, which neuroscientist Yadong Huang of UC San Francisco and Gladstone Institutes notes is “very challenging” given that Alzheimer’s stems from numerous alterations that disrupt brain health. By using letrozole and irinotecan in tandem, the researchers targeted different cellular mechanisms; letrozole appeared to counter the disease in neurons, while irinotecan functioned within glia. This dual-action strategy successfully reduced tau protein levels and boosted performance in learning and memory tasks during trials with mouse models.
What are the next steps for clinical translation?
While the results in mice are encouraging, the researchers acknowledge that these medications carry side effects that must be carefully weighed against potential benefits. According to the research team, the next logical step is to transition into clinical trials for human patients. This approach could facilitate more personalized treatment plans, tailored to the specific gene expression alterations present in each individual case. Sirota remains hopeful that if independent data sources, such as clinical records and single-cell expression data, continue to guide researchers toward the same pathways, these findings can be “swiftly translated into a real solution for millions of patients.”
Frequently Asked Questions
- Are these drugs currently available? Yes, letrozole and irinotecan are already approved by regulators in the U.S. for cancer treatment.
- What did the study show in mice? The combination therapy reversed some brain changes, significantly reduced harmful tau protein clumps, and improved learning and memory.
- Is this treatment currently approved for Alzheimer’s? No. The findings are based on research published in Cell and require clinical trials to determine safety and efficacy for Alzheimer’s patients.
Have thoughts on the future of personalized medicine? Share your perspective in the comments below or sign up for our newsletter to stay updated on the latest breakthroughs in neurodegenerative research.
